Literature DB >> 32455145

The HIV Outpatient Study-25 Years of HIV Patient Care and Epidemiologic Research.

Kate Buchacz1, Carl Armon2, Frank J Palella3, Richard M Novak4, Jack Fuhrer5, Ellen Tedaldi6, Douglas Ward7, Cynthia Mayer8, Linda Battalora2,9, Kimberly Carlson2, Stacey Purinton2, Marcus Durham1, Jun Li1.   

Abstract

Background: The clinical epidemiology of treated HIV infection in the United States has dramatically changed in the past 25 years. Few sources of longitudinal data exist for people with HIV (PWH) spanning that period. Cohort data enable investigating new exposure and disease associations and monitoring progress along the HIV care continuum.
Methods: We synthesized key published findings and conducted primary data analyses in the HIV Outpatient Study (HOPS), an open cohort of PWH seen at public and private HIV clinics since 1993. We assessed temporal trends in health outcomes (1993-2017) and mortality (1994-2017) for 10 566 HOPS participants.
Results: The HOPS contributed to characterizing new conditions (eg, lipodystrophy), demonstrated reduced mortality with earlier HIV treatment, uncovered associations between select antiretroviral agents and cardiovascular disease, and documented remarkable shifts in morbidity from AIDS opportunistic infections to chronic noncommunicable diseases. The median CD4 cell count of participants increased from 244 cells/mm3 to 640 cells/mm3 from 1993 to 2017. Mortality fell from 121 to 16 per 1000 person-years from 1994 to 2017 (P < .001). In 2010, 83.7% of HOPS participants had a most recent HIV viral load <200 copies/mL, compared with 92.2% in 2017. Conclusions: Since 1993, the HOPS has been detecting emerging issues and challenges in HIV disease management. HOPS data can also be used for monitoring trends in infectious and chronic diseases, immunologic and viral suppression status, retention in care, and survival, thereby informing progress toward the Ending the HIV Epidemic initiative. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.

Entities:  

Keywords:  HIV epidemiology; antiretroviral therapy; clinical outcomes; viral suppression

Year:  2020        PMID: 32455145      PMCID: PMC7235508          DOI: 10.1093/ofid/ofaa123

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   3.835


  57 in total

1.  Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.

Authors:  B G Yangco; J C Von Bargen; A C Moorman; S D Holmberg
Journal:  Ann Intern Med       Date:  2000-02-01       Impact factor: 25.391

2.  Incidence of Hepatitis C Virus Infection in the Human Immunodeficiency Virus Outpatient Study Cohort, 2000-2013.

Authors:  Taraz Samandari; Ellen Tedaldi; Carl Armon; Rachel Hart; Joan S Chmiel; John T Brooks; Kate Buchacz
Journal:  Open Forum Infect Dis       Date:  2017-06-10       Impact factor: 3.835

3.  AIDS in America - Back in the Headlines at Long Last.

Authors:  Wafaa M El-Sadr; Kenneth H Mayer; Miriam Rabkin; Sally L Hodder
Journal:  N Engl J Med       Date:  2019-05-01       Impact factor: 91.245

4.  Clinical assessment of HIV-associated lipodystrophy in an ambulatory population.

Authors:  K A Lichtenstein; D J Ward; A C Moorman; K M Delaney; B Young; F J Palella; P H Rhodes; K C Wood; S D Holmberg
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

5.  Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.

Authors:  Ellen M Tedaldi; Rose K Baker; Anne C Moorman; Carlos F Alzola; Jack Furhrer; Robert E McCabe; Kathleen C Wood; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2003-01-14       Impact factor: 9.079

6.  Sexual risk behavior and viremia among men who have sex with men in the HIV Outpatient Study, United States, 2007-2010.

Authors:  Marcus D Durham; Kate Buchacz; Jim Richardson; DerShung Yang; Kathy Wood; Bienvenido Yangco; John T Brooks
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

7.  Cardiovascular Disease Risk Prediction in the HIV Outpatient Study.

Authors:  Angela M Thompson-Paul; Kenneth A Lichtenstein; Carl Armon; Frank J Palella; Jacek Skarbinski; Joan S Chmiel; Rachel Hart; Stanley C Wei; Fleetwood Loustalot; John T Brooks; Kate Buchacz
Journal:  Clin Infect Dis       Date:  2016-09-09       Impact factor: 9.079

8.  Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study.

Authors:  Magdalena E Sobieszczyk; Donald R Hoover; Kathryn Anastos; Kathleen Mulligan; Tianren Tan; Qiuhu Shi; Wei Gao; Charles Hyman; Mardge H Cohen; Stephen R Cole; Michael W Plankey; Alexandra M Levine; Jessica Justman
Journal:  J Acquir Immune Defic Syndr       Date:  2008-07-01       Impact factor: 3.731

9.  Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?

Authors:  Bienvenido G Yangco; Kate Buchacz; Rose Baker; Frank J Palella; Carl Armon; John T Brooks
Journal:  AIDS Patient Care STDS       Date:  2014-05-15       Impact factor: 5.078

10.  A Matter of Perspective: Comparison of the Characteristics of Persons with HIV Infection in the United States from the HIV Outpatient Study, Medical Monitoring Project, and National HIV Surveillance System.

Authors:  Kate Buchacz; Emma L Frazier; H Irene Hall; Rachel Hart; Ping Huang; Dana Franklin; Xiaohong Hu; Frank J Palella; Joan S Chmiel; Richard M Novak; Kathy Wood; Bienvenido Yangco; Carl Armon; John T Brooks; Jacek Skarbinski
Journal:  Open AIDS J       Date:  2015-12-07
View more
  3 in total

1.  Hepatitis C Virus Testing Among Men With Human Immunodeficiency Virus Who Have Sex With Men: Temporal Trends and Racial/Ethnic Disparities.

Authors:  Jun Li; Carl Armon; Frank J Palella; Ellen Tedaldi; Richard M Novak; Jack Fuhrer; Gina Simoncini; Kimberly Carlson; Kate Buchacz
Journal:  Open Forum Infect Dis       Date:  2021-04-17       Impact factor: 3.835

2.  Adherence to Lipid-Lowering Medication in People Living with HIV: An Outpatient Clinic Drug Direct Distribution Experience.

Authors:  Gianluca Cuomo; Alessandro Raimondi; Marianna Rivasi; Giovanni Guaraldi; Vanni Borghi; Cristina Mussini
Journal:  J Res Pharm Pract       Date:  2021-05-13

3.  Development of type 2 diabetes and insulin resistance in people with HIV infection: Prevalence, incidence and associated factors.

Authors:  Göran Bratt; Johanna Brännström; Catharina Missalidis; Thomas Nyström
Journal:  PLoS One       Date:  2021-06-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.